A clinical trial conducted by Starpharma (ASX: SPL) using their technology, AZD0466, for the treatment of advanced haematological malignancies, has been placed on a voluntary partial hold. The trial, registered as NCT04865419, is currently in the dose escalation phase. However, the reported asymptomatic events leading to the hold were determined to be unrelated to Starpharma's DEP® dendrimer. This partial hold does not impact the company's platform technology or other clinical DEP® programs and partnerships.
Another clinical study involving AZD0466 for non-Hodgkin's lymphoma (NCT05205161) is unaffected and continues enrolling patients. Starpharma will release further details when more information becomes available. AstraZeneca is the study sponsor. Starpharma is a biopharmaceutical company focused on developing pharmaceutical and medical products, utilizing its proprietary dendrimer technology, to address unmet patient needs in oncology and infectious diseases.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
